Berry Jesse L, Shih Grace, Moysidis Stavros N, Jubran Rima, Wong Kenneth, Lee Thomas C, Murphree A Linn, Kim Jonathan W
a The Vision Center at Children's Hospital Los Angeles , Los Angeles , California , USA.
b The USC Eye Institute , University of Southern California Keck School of Medicine , Los Angeles , California , USA.
Ophthalmic Genet. 2016 Dec;37(4):400-403. doi: 10.3109/13816810.2015.1115881. Epub 2016 Mar 2.
The purpose of this study was to evaluate patterns of subretinal fluid (SRF) resolution in Group D retinoblastoma eyes. Fifty-three Group D eyes were evaluated for the presence of SRF at diagnosis. They were subsequently treated with systemic chemoreduction (CRD) and the duration of SRF was evaluated. Logistic regression analysis was used to assess the association between duration of SRF and enucleation. Among the 53 Group D eyes, 42 eyes exhibited SRF at diagnosis (79%). After the first cycle of CRD, 27/42 eyes showed SRF (64%); 8/42 eyes demonstrated SRF after three cycles of CRD (19%), and only 3/42 eyes had SRF after six cycles (7%). Ten eyes were enucleated (10/53 or 19%). Only 1 of 10 eyes demonstrated persistent SRF at the time of enucleation. This retrospective analysis of patterns of subretinal fluid in retinoblastoma eyes demonstrates that 80% of Group D eyes present with SRF. Of these eyes, approximately 60% have persistent fluid after one cycle of CRD and less than 10% have persistent fluid after six cycles. However, presence or persistence of SRF during chemoreduction was not found to be a risk factor for enucleation in Group D retinoblastoma eyes.
本研究的目的是评估D组视网膜母细胞瘤患眼中视网膜下液（SRF）的消退模式。对53只D组患眼在诊断时进行SRF检查。随后对其进行全身化疗减积（CRD）治疗，并评估SRF的持续时间。采用逻辑回归分析评估SRF持续时间与眼球摘除之间的关联。在53只D组患眼中，42只眼在诊断时出现SRF（79%）。在第一个CRD周期后，27/42只眼仍有SRF（64%）；在三个CRD周期后，8/42只眼有SRF（19%），而在六个周期后只有3/42只眼有SRF（7%）。10只眼被摘除眼球（10/53或19%）。在这10只被摘除眼球的眼中，只有1只在摘除时仍有持续性SRF。这项对视网膜母细胞瘤患眼中视网膜下液模式的回顾性分析表明，80%的D组患眼存在SRF。在这些眼中，约60%在一个CRD周期后仍有持续性积液，而在六个周期后有持续性积液的不到10%。然而，在D组视网膜母细胞瘤患眼中，化疗减积期间SRF的存在或持续并未被发现是眼球摘除的危险因素。
